News Release

Get Adobe ReaderTo view and print the files,
you must have Adobe Reader.

2005

March 18,2005 Astellas Pharma Inc.Appoints Representative Directors and Corporate Officers(PDF 47KB)
March 17,2005 Astellas Pharma Inc.:Organization of Overseas Group Companies and Their Top Management(PDF 22KB)
February 17,2005 Yamanouchi Terminates Marketing Agreement on the Penem-Type Antibiotic Farom
February 7,2005 Yamanouchi and Nippon Kayaku Sign a License Agreement on the Hepatic Artery Plugging Material Gelpart (Porous Gelatin Particles)
January 31,2005 Yamanouchi Transfers Subsidiary's Shares
(PDF 20KB )
January 31,2005 Notice of the Results of an Early Retirement Program(PDF 11KB)
January 24,2005 Yamanouchi and RIKEN Elucidate the Heart of the Genetic Network of Biological Clock by Systems Biology -Research Results Published in the Nature Genetics
January 20,2005 Yamanouchi Launches Vesicare for the Treatment of Overactive Bladder in the US

2004

December 20,2004 Reorganization of Astellas Group Companies in Japan(PDF 24KB)
December 15,2004 Yamanouchi Adds 9 Million IU Version to Its Hepatitis C Treatment Advaferon Injection Series
December 1,2004 Yamanouchi Terminates Marketing Agreement on the Hypercholesterolemia Treatment Cholebine
November 22,2004 Yamanouchi Receives Approval for Vesicare from US FDA for the Treatment of Overactive Bladder
November 09,2004 Mid-term Management Plan for Astellas Pharma Inc.(PDF 23KB)
November 4,2004 Yamanouchi to spin off two Formulation Plants by the Corporate Separation Method(PDF 31KB)
October 26,2004 Notice of Revision of the Business Results Forecast(PDF 19KB)
September 29,2004 Yamanouchi and Fujisawa to Start Operation of OTC Drug Joint Venture Zepharma Management Team, Organizational Structure, Business Sites Announced(PDF 60KB)
September 28,2004 Announcement Regarding the New Appointment of the Representative Director
September 22,2004 Yamanouchi Obtains Approval for an Additional Dosage Form Using Its Proprietary OCAS Technology for Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in the Netherlands
September 21,2004 Yamanouchi Obtains Approval for the Orally Disintegrating Tablet Harnal D Tablet, a Treatment for Functional Symptoms of Benign Prostatic Hyperplasia, in Japan
September 15,2004 Business Philosophy, Brand Mark, and Corporate Message of Astellas(PDF 53KB)
August 30,2004 Yamanouchi Applies NDA for YM905 in Japan for the Treatment of Urinary Frequency and Urinary Incontinence
August 26,2004 Yamanouchi Launches Vesicare in EU for the Treatment of Urinary Frequency and Urinary Incontinence
August 16,2004 Yamanouchi Concludes Co-promotion Agreement with US Boehringer Ingelheim for FLOMAX for the Treatment of Functional Symptoms of Benign Prostatic Hyperplasia (PDF 21KB)
July 26,2004 Large-scale clinical trial on the angiotensin II receptor blocker MICARDIS in Japan, called INNOVATION, completes subject recruitment
- First study to involve only Japanese subjects to evaluate the effect of the angiotensin II receptor blocker to type II diabetic nephropathy - (PDF 63KB)
July 20,2004 Yamanouchi Invents a Method to Accurately Determine Internal Body Time and Rhytem Disorders Using DNA Chips -Research Results Published in the PNAS
July 9,2004 Yamanouchi Obtains Marketing Authorization for Vesicare in 17 EU Member States
July 1,2004 Release for the Determination of Exercise Price, etc. of the Stock Option(Stock Acquisition Rights)
(PDF 8KB)
June 24,2004 Release for the Allotment of the Stock Option(Stock Acquisition Rights)(PDF 9KB)
June 18,2004 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 8KB)
June 18,2004 Yamanouchi Completes Transfer of Shares of Bear Creek Corporation
May 31,2004 Yamanouchi Restructures Its Partnership with Pfizer
May 28,2004 Yamanouchi Completes Transfer of Shares of Shaklee in Japan and US
May 24,2004 Yamanouchi and Fujisawa Finalize Merger Agreement The New Company to be Named "Astellas Pharma Inc." (PDF 29KB)
May 24,2004 Release for the Acquisition of the Company's Own Shares (PDF 8KB)
May 17,2004 Fujisawa and Yamanouchi Will Establish "Zepharma Inc.",an OTC pharmaceutical Company(PDF 46KB)
May 13,2004 Release for the Stock Option(Stock Acquisition Rights)(PDF 17KB)
April 2,2004 Yamanouchi Passed a Resolution Regarding the Sale of Consumer Business(PDF 27KB)
February 24,2004 Yamanouchi and Fujisawa Enter into A Basic Agreement to Merge on April 1,2005(PDF 33KB)
February 2,2004 Yamanouchi Submits a MAA for an Additional Dosage Form Using Its Proprietary OCAS Technology for Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Europe
February 2,2004 Yamanouchi Submits New Drug Application to the FDA for YM 087 to Treat Hyponatremia
January 20,2004 Yamanouchi Obtains Marketing Authorization for the Treatment of Urinary Frequency and Urinary Incontinence, Vesicare, in the Netherlands

2003

December 8,2003 Yamanouchi Terminates Marketing Agreement the Non-Ionic Contrast Medium OPTIRAY
November 20,2003 Yamanouchi Takes Over Marketing of Maalox for Oral Suspension from Aventis Pharma to Start Exclusive Marketing in Japan
November 18,2003 Regarding a news paper report
November 11,2003
 Yamanouchi Integrates Domestic Formulation Facilities by Spinning Off Two Formulation Plants
November 6,2003
 Clinical data of Micardis(telmisartan) presented at the Japanese Society of Hypertension.
October 27,2003
 Notice of Revision of the Business Results Forecast (PDF 22KB)
October 20,2003
 Yamanouchi Receives Approvable Letter from US FDA for the Treatment of Urinary Frequency and Urinary Incontinence Vesicare
October 16,2003 Fujisawa and Yamanouchi Enter into a Basic Agreement to Integrate OTC Businesses and Establish a New Joint Venture
August 21,2003 Yamanouchi and Medtronic Sofamor Danek Conclude License Agreement on the Bone Morphogenetic Protein rhBMP -2
August 8,2003 Co-Promotion Agreement in US with GlaxoSmithKline on Vesicare (YM905) for the Treatment of Urinary Frequency and Urinary Incontinence
July 1,2003 Release for the Determination of Exercise Price, etc. of the Stock Option(Stock Acquisition Rights)
(PDF 8KB)
June 27,2003 Release for the Stock Option(Stock Acquisition Rights) (PDF 10KB)
May 15,2003 Release for the Stock Option(Stock Acquisition Rights)(PDF 18KB)
May 15,2003 Release for the Acquisition of the Company's Own Shares(PDF 9KB)
May 1,2003 Yamanouchi Licenses the Drug for Alzheimer's Disease PYM50028 from Phytopharm of the UK
April 21,2003 Yamanouchi to Terminate Marketing Agreement on
the Oral Hypoglycemic Euglucon and the Cardiotonic Glycoside Lanirapid
March 18,2003 Yamanouchi Discovers Three New Target Genes for Drug Screening in Cooperation with Metabolex
- Accelerating Discovery of New Compounds in The Field of Diabetes and Obesity-
February 25,2003 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
February 20,2003 Yamanouchi Closes Plant of Its Subsidiary in Taiwan
February 6,2003 Yamanouchi Grants Exclusive Promotion Right for InductOsTM, a Preparation of the Bone Morphogenetic Protein BMP-2, in Europe to Medtronic
February 5,2003 Yamanouchi Contracts Out All Distribution Functions to Mitsubishi Logistics Corp
January 29,2003 Yamanouchi Files a MMA for the Treatment of Urinary Frequency and UrinaryIncontinence,YM 905(solifenacin succinate),in Europe Following the US
January 27,2003 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
January 23,2003 Taiho and Yamanouchi Sign a License Agreement on IPD-1151T, a drug for Interstitial Cystitis
January 9,2003 Yamanouchi to File NDA for the Treatment of Urinary Frequency and UrinaryIncontinence,YM905(solifenacin succinate),with the US FDA

2002

December 19,2002 Pharmacia K.K. and Yamanouchi Submit New Drug Application in Japan for Celecoxib
December 17,2002 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
December 9,2002 Nippon Boehringer Ingelheim and Yamanouchi Launched "MICARDIS Capsule 20mg and 40mg," a New Long Acting Angiotensin II Receptor Blocker
November 28,2002 Yamanouchi Introduces the Ariba Buyer e-Procurement Solution to Enhance Efficiency of Indirect Materials Purchases
October 24,2002 Notice of Revision of the Business Results Forecast(PDF 42KB)
October 9,2002 Manufacturing and Import of Micardis, New Oral Therapy for Hypertension, is Approved
September 25,2002 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
August 26,2002
 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 10KB)
August 22,2002
 Yamanouchi Gives Up Acquisition of Approval of YM175 for Osteoporosis
August 1,2002
 Yamanouchi Identifies Clock-Controlled Elements That Genenerate Gene Expression During Circadian Night Using "Systems Biology", A New Genomic Approach -Research Results Published In The Nature
July 1,2002
 Zeria and Yamanouchi Sign Letter of Intent for Development and Marketing of The Gastroprokininetic Z-338
May 16,2002 Notice Regarding the Acquisition of the Company's Own Shares(PDF 9KB)
March 25,2002 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 10KB)
March 19,2002 Yamanouchi Tifs Up with Metabolex for Genomic Drug Discovery Collabative Research to Start for Discovery of New Drugs for Diabetes and Obesity
February 25,2002 Yamanouchi Pharmaceutical Co., Ltd. Notice Regarding Contribution in Kind of Shares of the Subsidiary
February 25,2002 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
February 19,2002 Yamanouchi to close its research institute in the UK to use its know-how in genomic drug discovery in Tsukuba Research Center,Japan
January 28,2002 Agreement on Information Disclosure Regarding Gene Functions Obtained Using Knockout Mice
(PDF 22KB)
January 24,2002 LOI Signed between Boehringer Ingelheim and Yamanouchi on Co-Promotion of Angiotensin II Receptor Blocker Telmisartan"

2001

December 18,2001 Notice Regarding Purchase of the Company's Own Shares in the Market(PDF 9KB)
December 7,2001 Yamanouchi and Amgen Launch the Recombinant Interferon-
Advaferon Injection
November 12,2001 Yamanouchi Starts Collaborative Research whith us Academia for the Discovery of Drugs for Alzheimer's Disease
August 6,2001 Taisho and Yamanouchi Sign Agreement to Engage in Joint Research for New Drug Discovery
June 26,2001 Yamanouchi Tie-ups with Celera Genomics
for Genomic Drug Discovery
January 30,2001 Yamanouchi America, Inc.
Names Nicholas L. Teti President and Director
January 25,2001 Revision of Business Results Forecast(PDF 15KB)

2000

November 22,2000 Yamanouchi Establishes Venture Capital Company in the US
October 25,2000 Notice of Revision of the Business Results Forecast (PDF 15KB)
October 21,2000 Revision of Business Results Forecast(PDF 16KB)
September 26,2000 Yamanouchi Sale of Shire Pharmaceutical Stake
June 27,2000 Nishine Plant of Yamanouchi Pharmaceutical Co., Ltd. Obtained Attestation of ISO9002
June 7,2000 Yamanouchi Pharmaceutical Co., Ltd. and Glaxo Wellcome K.K. initiate research collaboration study on identifying potential drug target genes
February 25,2000 Announcement Regarding Change in Top Management of Yamanouchi Pharmaceutical Co., Ltd. (the "Company")
January 11,2000 Yamanouchi Pharmaceutical Co., Ltd.
reached a settlement on famotidine polymorphism patent with Gedeon Richter Ltd.

1999

June 11,1999 Opening extended Research and Development facilities of Yamanouchi Europe
January 28,1999 The Yamanouchi European Foundation Awards Research Grant to the 1st Clinic of Neurology, Brno, Czech Republic

1998

September 17,1998 A New Pharmaceutical Manufacturing Plant Completed in Norman, Oklahoma, U.S.A.
June 25,1998 Yamanouchi Begins Clinical Development of Ultrasound Contrast Agent
June 8,1998 Yamanouchi Shaklee Pharma and Johnson & Johnson-Merck Sign WOWTAB(R) Development Agreement
May 21,1998 Yamanouchi Shaklee Pharma and Glaxo Wellcome Sign Development Agreement
May 11,1998
 Yamanouchi and Merck KGaA to Conduct Co-Development of Jointly Discovered Products Worldwide
May 7,1998
 Yamanouchi Pharmaceutical Licenses Vasopressin Receptor Antagonist Now Under Development to U.S.-Based Warner-Lambert Company
January 20,1998 Yamanouchi Forming Research Alliance with Searle
January 19,1998 Unique Network Cooperation Between a Pharmaceutical Company and Three Universities on Innovative Drug Research

1997

November 26,1997 Yamanouchi Pharmaceutical Co., Ltd.,
Completes U.S. Research Center
October 9,1997 Yamanouchi's Treatment for Functional Symptoms of BPH Launched in the Unite d States, Completing a Presence in Three Major Markets: Asia, Europe, and th e United States
May 8,1997 Shenyang Yamanouchi Pharmaceutical
Completes New Factory
March 12,1997 Sales of Tamsulosin Begin in Italy; Product Now Available in Europe's Three Largest Markets
March 5,1997 Yamanouchi to Construct Pharmaceutical
Manufacturing Plant in Oklahoma